|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 292.01 USD | -1.79% |
|
-1.19% | -17.24% |
| 07-14 | United Therapeutics Offers Favorable Profile Ahead of Key Data, Oppenheimer Says | MT |
| 06-30 | United Therapeutics' Tyvaso to Benefit from Q2 Seasonality, UBS Says | MT |
Company Valuation: United Therapeutics Corporation
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 6,746 | 9,731 | 12,674 | 10,333 | 15,752 | 13,172 | - | - |
| Change | - | 44.26% | 30.24% | -18.47% | 52.44% | -16.38% | - | - |
| Enterprise Value (EV) 1 | 5,711 | 9,637 | 12,513 | 8,039 | 12,785 | 10,158 | 8,987 | 7,829 |
| Change | - | 68.75% | 29.85% | -35.75% | 59.04% | -20.55% | -11.53% | -12.88% |
| P/E ratio | 13.2x | 21.5x | 18.5x | 11.1x | 14.3x | 10.7x | 10.4x | 10.3x |
| PBR | 1.99x | 2.67x | 2.67x | 1.73x | 2.47x | 1.72x | 1.47x | 1.3x |
| PEG | - | -1.7x | 0.4x | 0.3x | 0.6x | 1x | 3.72x | 10.62x |
| Capitalization / Revenue | 4.55x | 5.77x | 6.55x | 4.44x | 5.47x | 4.09x | 3.84x | 3.7x |
| EV / Revenue | 3.85x | 5.72x | 6.46x | 3.45x | 4.44x | 3.15x | 2.62x | 2.2x |
| EV / EBITDA | 8.87x | 15.9x | 12.1x | 6.49x | 8.82x | 6.08x | 5.27x | 4.55x |
| EV / EBIT | 9.62x | 17.3x | 12.8x | 6.78x | 9.28x | 6.33x | 5.34x | 4.6x |
| EV / FCF | 8.2x | 20.2x | 18.9x | 10.8x | 11.8x | 8.08x | 6.79x | 5.51x |
| FCF Yield | 12.2% | 4.95% | 5.3% | 9.3% | 8.45% | 12.4% | 14.7% | 18.2% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 11.54 | 10.06 | 15 | 19.81 | 24.64 | 27.35 | 28.12 | 28.39 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 1,483 | 1,686 | 1,936 | 2,328 | 2,877 | 3,223 | 3,426 | 3,562 |
| EBITDA 1 | 643.5 | 605.8 | 1,031 | 1,238 | 1,450 | 1,670 | 1,705 | 1,722 |
| EBIT 1 | 593.6 | 555.9 | 979.7 | 1,185 | 1,377 | 1,605 | 1,683 | 1,703 |
| Net income 1 | 514.8 | 475.8 | 727.3 | 984.8 | 1,195 | 1,343 | 1,398 | 1,419 |
| Net Debt 1 | -1,035 | -94.8 | -161.2 | -2,294 | -2,967 | -3,014 | -4,185 | -5,342 |
| Reference price 2 | 151.79 | 216.08 | 278.09 | 219.89 | 352.84 | 292.01 | 292.01 | 292.01 |
| Nbr of stocks (in thousands) | 44,441 | 45,037 | 45,577 | 46,994 | 44,645 | 45,107 | - | - |
| Announcement Date | 2/24/21 | 2/24/22 | 2/22/23 | 2/21/24 | 2/26/25 | - | - | - |
1USD in Million2USD
Estimates
P/E ratio, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| 10.68x | 3.15x | 6.08x | -.--% | 13.17B | ||
| 36.13x | 11.98x | 27.23x | 0.77% | 693B | ||
| 14.63x | 4.31x | 11.78x | 3.15% | 394B | ||
| 27.14x | 6.49x | 13.73x | 3.45% | 334B | ||
| 15.94x | 5.78x | 11.57x | 3.18% | 287B | ||
| 14.37x | 3.52x | 8.72x | 3.82% | 259B | ||
| 16.56x | 4.4x | 10.31x | 3.49% | 223B | ||
| 21.78x | 4.08x | 12x | 2.32% | 215B | ||
| 10.26x | 3.33x | 7.2x | 4.02% | 201B | ||
| 22.54x | 5.77x | 11.13x | 3.25% | 158B | ||
| Average | 19.00x | 5.28x | 11.98x | 2.75% | 277.81B | |
| Weighted average by Cap. | 22.43x | 6.56x | 15.07x | 2.68% |
Year-on-year evolution of the PER
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- UTHR Stock
- Valuation United Therapeutics Corporation
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition